Robert D. Toto
University of Texas Southwestern Medical Center
Internal medicineUrologyEndocrinologySurgeryRenal functionCardiologyRandomized controlled trialIntensive care medicineAlbuminuriaType 2 diabetesHemodialysisKidney diseaseDiabetic nephropathyDialysisCreatinineNephropathyPopulationDiabetes mellitusMedicineBlood pressure
213Publications
61H-index
12.5kCitations
Publications 220
Newest
#1John J.V. McMurray (Glas.: University of Glasgow)H-Index: 202
#2David C. Wheeler (The George Institute for Global Health)H-Index: 4
Last. C. David Sjöström (AstraZeneca)H-Index: 18
view all 16 authors...
Abstract Objectives The purpose of this paper was to investigate the effects of dapagliflozin in chronic kidney disease (CKD) patients, with and without heart failure (HF). Background Patients with...
Source
Summary null null Background null Reductions in albuminuria are associated with a subsequent lower risk of kidney failure in patients with chronic kidney disease. The SGLT2 inhibitor dapagliflozin significantly reduced albuminuria in patients with type 2 diabetes and normal or near-normal kidney function. Whether this effect persists in patients with chronic kidney disease with and without type 2 diabetes is unknown. We assessed the effects of dapagliflozin on albuminuria in patients with chroni...
Source
#1Hiddo J.L. Heerspink (The George Institute for Global Health)H-Index: 74
#2Niels Jongs (UMCG: University Medical Center Groningen)H-Index: 5
Last. Robert D. Toto (UTSW: University of Texas Southwestern Medical Center)H-Index: 61
view all 14 authors...
Background null Dapagliflozin reduced the risk of kidney failure in patients with chronic kidney disease with and without type 2 diabetes in the DAPA-CKD trial. In this pre-specified analysis, we assessed the effect of dapagliflozin on the rate of change in estimated glomerular filtration rate (eGFR)-ie, the eGFR slope. null Methods null DAPA-CKD was a randomised controlled trial that enrolled participants aged 18 years or older, with or without type 2 diabetes, with a urinary albumin-to-creatin...
Source
#1Hiddo J.L. Heerspink (The George Institute for Global Health)H-Index: 74
#2David Z.I. Cherney (UHN: University Health Network)H-Index: 47
Last. John J.V. McMurray (Glas.: University of Glasgow)H-Index: 202
view all 17 authors...
This pre-specified analysis of DAPA-CKD assessed the impact of sodium-glucose cotransporter 2 inhibition on abrupt declines in kidney function in high-risk patients based on having chronic kidney disease (CKD) and substantial albuminuria. DAPA-CKD was a randomized, double-blind, placebo-controlled trial that had a median follow-up of 2.4 years. Adults with CKD (urinary albumin-to-creatinine ratio 200–5000 mg/g and estimated glomerular filtration rate 25–75 mL/min/1.73m2) were randomized to dapag...
Source
Abstract Kidney fibrosis constitutes the shared final pathway of nearly all chronic nephropathies, but biomarkers for the non-invasive assessment of kidney fibrosis are currently not available. To address this, we characterize five candidate biomarkers of kidney fibrosis: Cadherin-11 (CDH11), Sparc-related modular calcium binding protein-2 (SMOC2), Pigment epithelium-derived factor (PEDF), Matrix-gla protein, and Thrombospondin-2. Gene expression profiles in single-cell and single-nucleus RNA-se...
Source
#1Jarett D. Berry (UTSW: University of Texas Southwestern Medical Center)H-Index: 51
#2Vijay Nambi (BCM: Baylor College of Medicine)H-Index: 49
Last. Ambarish Pandey (UTSW: University of Texas Southwestern Medical Center)H-Index: 45
view all 15 authors...
Importance null Elevated high-sensitivity cardiac troponin T (hscTnT) and N-terminal pro-B-type natriuretic peptide (NTproBNP) levels are associated with risk of heart failure (HF) and mortality among individuals in the general population. However, it is unknown if this risk is modifiable. null Objective null To test the hypothesis that elevated hscTnT and NTproBNP levels would identify individuals with the greatest risk for mortality and HF and the largest benefit associated with intensive syst...
Source
#1Alexander H. Flannery (UK: University of Kentucky)H-Index: 13
#2Victor Ortiz-Soriano (UK: University of Kentucky)H-Index: 8
Last. Javier A. Neyra (UK: University of Kentucky)H-Index: 17
view all 0 authors...
BACKGROUND Preliminary studies have suggested that the renin-angiotensin system is activated in critical illness and associated with mortality and kidney outcomes. We sought to assess in a larger, multicenter study the relationship between serum renin and Major Adverse Kidney Events (MAKE) in intensive care unit (ICU) patients. METHODS Prospective, multicenter study at two institutions of patients with and without acute kidney injury (AKI). Blood samples were collected for renin measurement a me...
Source
#1Blue B. Lake (University of California, Berkeley)H-Index: 16
#2Rajasree Menon (UM: University of Michigan)H-Index: 27
Last. Dinh Diep (University of California, Berkeley)H-Index: 15
view all 44 authors...
Abstract null Understanding kidney disease relies upon defining the complexity of cell types and states, their associated molecular profiles, and interactions within tissue neighborhoods. We have applied multiple single-cell or -nucleus assays (>400,000 nuclei/cells) and spatial imaging technologies to a broad spectrum of healthy reference (n = 42) and disease (n = 42) kidneys. This has provided a high resolution cellular atlas of 100 cell types that include rare and novel cell populations. The ...
Source
Background In the Dapagliflozin And Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized placebo-controlled trial, the sodium-glucose cotransporter 2 inhibitor dapagliflozin significantly reduced risk of kidney failure and prolonged survival in CKD patients with or without type 2 diabetes. Methods In this prespecified analysis of dapagliflozin's effects in patients with stage 4 CKD (eGFR<30 mL/min per 1.73m2) at baseline, we randomized adults with eGFR of 25-75 mL/min p...
Source
#1Frederik Persson (Steno Diabetes Center)H-Index: 36
#2Peter Rossing (UCPH: University of Copenhagen)H-Index: 102
Last. Bergur V. Stefánsson (AstraZeneca)H-Index: 15
view all 14 authors...
OBJECTIVE null The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and cardiovascular outcomes with dapagliflozin versus placebo in participants with chronic kidney disease (CKD) with and without diabetes. We compared outcomes according to baseline glycemic status. null RESEARCH DESIGN AND METHODS null We enrolled participants with CKD, estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73m2, and urinary a...
Source
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.